Trial · NCT06785415
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
NCT06785415, Phase 1, Phase 2, Recruiting, Mayo Clinic
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma. Trials, record NCT06785415. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06785415
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
- NCT number
- NCT06785415
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 37 participants, estimated
- Lead sponsor
- Mayo Clinic
- Conditions
- Recurrent Multiple Myeloma
- Interventions
Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Chest Radiography, Computed Tomography, Daratumumab, Dexamethasone, Elotuzumab, Iberdomide, Magnetic Resonance Imaging, Positron Emission Tomography
- First posted
- 2025-01-21
- Last updated
- 2026-06-25
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum tolerated dose (Phase 1) | Up to 28 days | The maximum tolerated dose (MTD) of the combination of iberdomide, daratumumab, elotuzumab, and dexamethasone (IberDEd) will be defined as the highest tested dose level that is determined to have acceptable toxicity and tolerability based on dose limiting toxicity definitions. |
| Primary | Proportion of patients with very good partial response (VGPR) or better (Phase 2) | Up to 3 years | Will be defined as a patient who has achieved a VGPR, complete response (CR), or stringent complete response (sCR) and maintained it on two consecutive evaluations at any time during therapy per International Myeloma Working Group (IMWG) criteria. |
| Secondary | Overall response rate (Phase 2) | Up to 3 years | Will be assessed as stringent Complete Response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), Minimal Response (MR), stable disease (SD), or progressive disease (PD). |
| Secondary | Complete response rate (Phase 2) | Up to 3 years | Will be estimated by the total number of patients who achieve sCR or CR. |
| Secondary | Progression-free survival (Phase 2) | Up to 3 years | Defined as the time from registration to the earliest date of documentation of disease progression, relapse, or death due to any cause. |
| Secondary | Overall survival (Phase 2) | Up to 3 years | Overall survival (OS) is defined as the time from registration to death due to any cause. |
| Secondary | Time to response (Phase 2) | Up to 3 years | Defined in patients who have achieved a response (PR or better) as the time from registration to the first incidence of a response. |
| Secondary | Incidence of adverse events (AEs) (Phase 2) | Up to 3 years | Will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The maximum grade for each type of AE will be recorded for each patient. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06785415
GET https://conductscience.org/api/trials/v1/NCT06785415/registered